| Identification | Back Directory | [Name]
NVP-TNKS656 | [CAS]
1419949-20-4 | [Synonyms]
TNKS656
CS-1333
NVP-TNKS656
NVP-TNKS656 - TNKS 656
TNKS656; TNKS-656;TNKS 656
1-Piperidineacetamide, N-(cyclopropylmethyl)-4-(4-methoxybenzoyl)-N-[(3,5,7,8-tetrahydro-4-oxo-4H-pyrano[4,3-d]pyrimidin-2-yl)methyl]-
N-(cyclopropylmethyl)-2-(4-(4-methoxybenzoyl)piperidin-1-yl)-N-((4-oxo-4,5,7,8-tetrahydro-3H-pyrano[4,3-d]pyrimidin-2-yl)methyl)acetamide
N-(cyclopropylmethyl)-2-(4-(4-methoxybenzoyl)piperidin-1-yl)-N-((4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrimidin-2-yl)methyl)acetamide | [EINECS(EC#)]
604-604-1 | [Molecular Formula]
C27H34N4O5 | [MDL Number]
MFCD28167762 | [MOL File]
1419949-20-4.mol | [Molecular Weight]
494.58 |
| Chemical Properties | Back Directory | [Boiling point ]
700.7±70.0 °C(Predicted) | [density ]
1.37±0.1 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Store in freezer, under -20°C | [solubility ]
Soluble in DMSO | [form ]
crystalline solid | [pka]
6.66±0.10(Predicted) | [color ]
White to light yellow | [InChIKey]
DYGBNAYFDZEYBA-UHFFFAOYSA-N | [SMILES]
N4(CCC(CC4)C(=O)c5ccc(cc5)OC)CC(=O)N(CC3CC3)Cc1[nH][c](c2c(n1)CCOC2)=O |
| Hazard Information | Back Directory | [Description]
NVP-TNKS656 is an orally bioavailable inhibitor of tankyrase 2 (TNKS2; IC50 = 6 nM).1 It is selective for TNKS2 over poly(ADP-ribose) polymerase (PARP) 1 and 2 (IC50s = >19 and 32 nM, respectively). NVP-TNKS656 inhibits Wnt ligand-induced signaling with an IC50 value of 3.5 nM in an HEK293 cell reporter assay. In vivo, NVP-TNKS656 (350 mg/kg) reduces Axin 2 mRNA expression, a Wnt/β-catenin target gene, in MMTV-Wnt1 tumor bearing mice. | [Uses]
NVP-TNKS656 is a highly potent, selective, and orally active TNKS2 inhibitor with IC50 of 6 nM, and is > 300 fold selectivity against PARP1 and PARP2. | [Synthesis]
Example 5: Synthesis of N-cyclopropylmethyl-2-[4-(4-methoxybenzoyl)-piperidin-1-yl]-N-(4-oxo-tetrahydro-4H-pyrano[4,3-d]pyrimidin-2-ylmethyl)-acetamide. 2-(4-(4-methoxybenzoyl)piperidin-1-yl)acetic acid (0.071 g, 0.26 mmol, 1 eq.) and N,N-diisopropylethylamine (DIEA, 0.089 mL, 0.51 mmol, 2 eq.) were dissolved in 2 mL of N,N-dimethylformamide (DMF), followed by addition of O-(7-azabenzotriazol-1-yl)-N ,N,N',N'-tetramethyluronium hexafluorophosphate (HATU, 0.107 g, 0.281 mmol, 1.1 eq.). The reaction mixture was stirred at room temperature for 30 minutes. Then, a 1 mL DMF solution of 2-[(cyclopropylmethylamino)methyl]-3,5,7,8-tetrahydro-pyrano[4,3-d]pyrimidin-4-one (0.06 g, 0.26 mmol, 1 eq.) was added to the reaction mixture, and stirring was continued overnight at room temperature.After 18 h, the reaction mixture was diluted with 10 mL of water and dichloromethane (3 x 50 mL) was used for Extraction. The organic phases were combined, concentrated and purified by preparative high performance liquid chromatography (HPLC, 20-100% acetonitrile/water, 10 min, containing 0.1% trifluoroacetic acid, SunFire C18 OBD 50x50mm column at a flow rate of 60 mL/min) to afford the target compound N-(cyclopropylmethyl)-2-(4-(4-methoxybenzoyl)piperidin-1-yl)- N-((4-oxo-4,5,7,8-tetrahydro-3H-pyrano[4,3-d]pyrimidin-2-yl)methyl)acetamide as a white solid (0.03 g, 24% yield).1H NMR (400 MHz, methanol-d4) δ ppm 7.94-8.07 (m, 2H), 6.98-7.10 (m, 2H), 4.64-4.70 (m, 1H), 4.54-4.60 (m, 1H), 4.44-4.52 (m, 2H), 4.28-4.37 (m, 1H), 3.94-3.99 (m, 1H), 3.91-3.95 (m, 2H), 3.88 (s, 3H), 3.67-3.80 (m, 2H), 3.40-3.61 (m, 1H). 3.33-3.40 (m, 2H), 3.09-3.27 (m, 2H), 2.50-2.72 (m, 2H), 1.92-2.26 (m, 4H), 0.83-1.15 (m, 1H), 0.12-0.67 (m, 4H). High resolution mass spectrometry (HRMS) calculated value C27H35N4O5 [M+H]+ 495.2607, measured value 495.2606. mass spectrometry (ESI) m/z 495.3 ([M+H]+). Retention time: 2.89 min (5-75% acetonitrile/water, 7.75 min with 0.1% formic acid, Inertsil ODS3 100x3mm C18 column, flow rate 1.0 mL/min). | [in vitro]
the ic50 value of nvp-tnks656 against parp1, tnks2, parp2, and stf was > 19, 0.006, 32, and 0.0035 μm, respectively [1]. | [in vivo]
the clearance and volume of distribution of nvp-tnks656 were 10 ml/min/kg and 0.6 l/kg after intravenous administration in mice. the exposure and oral bioavailability was 32% and 53%, respectively. in the mouse mammary tumor virus (mmtv)-wnt1 transgenic model, oral administration of nvp-tnks656 (350 mg/kg) activated the wnt signaling over a 24-h time course. nvp-tnks656 treatment reduced the wnt/beta-catenintarget gene axin2 mrna level by 70-80% [1]. | [IC 50]
TNKS2: 6 nM (IC50); PARP2: 32 μM (IC50) | [References]
shultz m d, cheung a k, kirby c a, et al. identification of nvp-tnks656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor[j]. journal of medicinal chemistry, 2013, 56(16): 6495-6511. |
|
| Company Name: |
Moltt Biocem Co., Ltd.
|
| Tel: |
+86-21-38682181 15900741819 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15856/0_EN.htm |
|